This medical infographic illustrates the gut-brain-liver axis focusing on bile acid (BA) synthesis and circulation. In the liver, cholesterol is converted into primary BAs and conjugated BAs, which are then released via bile into the intestines. In the gut, microbial modification transforms them into secondary BAs; 95% are reabsorbed through the enterohepatic circulation, while 5% are excreted. A systemic circulation pathway shows primary, secondary, and conjugated BAs reaching the Central Nervous System (CNS). The diagram suggests local synthesis of cholesterol and BAs may also occur within the brain. Surrounding the central physiological diagram are boxes detailing therapeutic research for various neuropathologies, including Multiple Sclerosis (MS), Huntington's Disease (HD), Amyotrophic Lateral Sclerosis (ALS), Parkinson's Disease (PD), Alzheimer's Disease (AD), Spinal Cord Injury (SCI), and depression. Each box indicates treatment efficacy in animal models (+) and Randomized Clinical Trials (RCT), with signs denoting positive effects (+), no effect (-), or no data available (n.d.).

A pathophysiology diagram illustrating the metabolic pathways of bile acids and cholesterol derivatives in the context of cerebrotendinous xanthomatosis (CTX) and intestinal bacterial metabolism. On the left, an illustration of a human subject with CTX shows the excessive accumulation of 7α-hydroxy-4-cholesten-3-one (C4), a marker for bile acid synthesis. On the right, a rabbit model demonstrates the bacterial conversion of radiolabeled C4. The sequence shows C4 being transformed into cholesta-4,6-dien-3-one through the elimination of the 7α-hydroxyl group and introduction of a double bond at C6-C7. This is followed by reduction to cholestanol, involving the saturation of the steroid ring and reduction of the C3-ketone to a hydroxyl group. A boxed inset at the bottom left illustrates a 'Proposed analogous reaction during bile acid 7α-dehydroxylation' by gut microbiota. It depicts the conversion of 3-oxo-4-cholic acid (3-oxo-4-CA) to 3-oxo-4,6-deoxycholic acid (3-oxo-4,6-DCA), highlighting a mechanism involving a 3-oxo-Δ4-steroid intermediate. This educational visual explains the biochemical link between human metabolic errors and microbial bile acid biotransformation.

This pathophysiology diagram illustrates the protective role of Clostridium scindens (C. scindens) against acute Clostridioides difficile (C. difficile) infection through bile acid (BA) metabolism. The process begins with Primary Bile Acids (PBAs) being converted into Secondary Bile Acids (SBAs) by intestinal bacteria that possess Bile Salt Hydrolase (BSH) and 7Ͱ-dehydroxylase activity. C. scindens is shown as a critical driver of this conversion. The diagram highlights three specific inhibitory pathways (labeled A, B, and C) through which C. scindens and SBAs mitigate C. difficile infection: (A) direct inhibition of C. difficile bacterial counts, (B) suppression of C. difficile toxin production (specifically TcdA and TcdB), and (C) overall reduction of the infection's clinical impact, depicted in a mouse model. Key enzymatic components represented include BSHs and 7Ͱ-dehydroxylase, which facilitate the chemical transformation of BAs. This visual explains the therapeutic potential of microbial restoration in managing gastrointestinal dysbiosis and antibiotic-associated infections.

A medical pathophysiology diagram illustrating the complex interactions between Bacteroidetes species, bile acid metabolism, and intestinal health. The central pathway shows primary bile acids (PBA) being converted to secondary bile acids (SBA) by intestinal bacteria exhibiting bile salt hydrolase (BSH) activity. The diagram is divided into three functional pathways. Pathway A depicts Bacteroides ovatus, B. thetaiotaomicron, and B. fragilis producing BSH enzymes that facilitate SBA production, which subsequently inhibits colitis (modeled by DSS induction). Pathway B shows Bacteroides fragilis NCTC9343 triggering heightened BSH gene expression, which correlates with the development of Colorectal Cancer, characterized by visible cellular dysplasia. Pathway C illustrates Bacteroides dorei modulating the FXR (Farnesoid X Receptor) signaling pathway on the intestinal epithelium to alleviate experimental colitis. The diagram utilizes a rodent model (mouse) to contextualize these microbiome-host interactions, emphasizing the dual role of Bacteroidetes in promoting either anti-inflammatory outcomes or oncogenesis depending on specific strains and gene expression profiles.

Gross pathology photograph of a gallbladder lumen containing numerous dark pigment stones. The specimen illustrates cholelithiasis with pigment-type calculi arising in the setting of chronic hemolysis. Pigment stones are rich in bilirubin calcium salts; excessive bilirubin turnover leads to supersaturation of bile with unconjugated bilirubin, promoting precipitation and stone formation. In chronic hemolytic states, conjugated bilirubin secretion increases and deconjugation within the biliary tree yields substantial deconjugated bilirubin, precipitating as black to brown pigment stones that fill the luminal cavity. The surrounding gallbladder wall may appear thickened or fibrotic in chronic inflammation, though mural details are limited in this image. The stones range from granular to angular and vary in size; their surface may be smooth or faceted and they impart a mottled, dark appearance to the lumen against a lighter mucosal backdrop. Clinically, pigment stones correlate with hemolytic anemias (e.g., sickle cell disease, hereditary spherocytosis) and can cause biliary colic or cholecystitis when obstructing cystic duct. Differential considerations include cholesterol stones, mixed pigment stones, and brown pigment stones due to infection. These findings underscore the diagnostic significance of gallbladder pigment lithiasis as a marker of bilirubin metabolism disturbances and chronic biliary disease. This image aids diagnostic and research interpretation.

Summary : This flowchart outlines the clinical decision-making process for evaluating jaundice or pale stools in 2- to 4-week-old infants during the "By 1 month" well-child visit, focusing on when to measure direct or conjugated bilirubin and when to urgently contact gastroenterology. flowchart: # Nodes : • Start (ellipse): "2- to 4-week-old infant at the 'By 1 month' well-child visit" • Step 1 (diamond): "Any jaundice in eyes or skin?" • Step 2 (diamond): "Stools pale, gray, or white (by inspection or report)?" • Step 3A (diamond): "Prior direct or conjugated bilirubin level(s) available?" • Step 3B (diamond): "Initial direct or conjugated bilirubin level above lab reference range?" • Action (rectangle, red border): "Measure a direct or conjugated bilirubin within 48 hours**" • Decision (diamond): "Direct or conjugated bilirubin level ≥1 mg/dL?" • Decision (diamond): "Direct or conjugated bilirubin level within lab reference range?" • Action (ellipse, red border): "Contact Gastroenterology urgently" • Action (ellipse): "No further testing needed" • Action (ellipse): "Monitor clinically; No further testing needed unless jaundice or pale stools develop" # Connectors : • Start → Step 1 • Step 1 Yes → Measure a direct or conjugated bilirubin within 48 hours** • Step 1 No → Step 2 • Step 2 Yes → Measure a direct or conjugated bilirubin within 48 hours** • Step 2 No → Step 3A • Step 3A Yes → Step 3B • Step 3A No → Monitor clinically; No further testing needed unless jaundice or pale stools develop • Step 3B Yes → Measure a direct or conjugated bilirubin within 48 hours** • Step 3B No → No further testing needed • Measure a direct or conjugated bilirubin within 48 hours** → Direct or conjugated bilirubin level ≥1 mg/dL? • Direct or conjugated bilirubin level ≥1 mg/dL? Yes → Contact Gastroenterology urgently • Direct or conjugated bilirubin level ≥1 mg/dL? No → Direct or conjugated bilirubin level within lab reference range? • Direct or conjugated bilirubin level within lab reference range? Yes → No further testing needed • Direct or conjugated bilirubin level within lab reference range? No → Contact Gastroenterology urgently # Layout : • Top-down hierarchical structure. • Decision diamonds branch to actions or further decisions. • Red-bordered nodes highlight urgent actions. • Ellipses used for start/end points and urgent actions. # Analysis : • The flowchart provides a systematic approach to evaluating jaundice or pale stools in young infants. • It emphasizes early measurement of direct or conjugated bilirubin if jaundice or pale stools are present. • Urgent gastroenterology contact is required if bilirubin is ≥1 mg/dL or above reference range. • Clinical monitoring is recommended if no concerning findings are present. • The process ensures timely identification and management of possible liver or biliary disease.

This clinical photograph displays a coronal gross section of a brain, serving as a classic pathological demonstration of kernicterus (bilirubin encephalopathy). The most striking visual feature is the intense, symmetrical yellow-orange staining (icterus) localized specifically to the basal ganglia, most notably the putamen. This discoloration results from the deposition of unconjugated bilirubin in specific subcortical nuclei. The surrounding cerebral cortex, white matter tracts, and ventricular spaces appear largely unaffected and maintain a normal pale cream coloration. This visual pattern is characteristic of neonatal jaundice where the blood-brain barrier is permeable to lipid-soluble unconjugated bilirubin, leading to localized neurotoxicity. The image highlights the selective vulnerability of deep gray matter structures to hyperbilirubinemia in the neonatal period, a key concept in pediatric neurology and pathology.